Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Tufman

Showing results (31-40 of 146) with videos related to

Pageof 15
Sort By:
Scientific Reports|May 26, 2021
Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective studyDiego Kauffmann-Guerrero, Kathrin Kahnert, Rosemarie Kiefl, et al.
Therapeutic Advances in Medical Oncology|June 28, 2021
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studiesChristiane Bickert, Kathrin Kahnert, Diego Kauffmann-Guerrero, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal AssessmentDiego Kauffmann-Guerrero, Julian Taugner, Chukwuka Eze, et al.
The Journal of Surgical Research|October 4, 2011
Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injurySebastian Pratschke, Manfred Bilzer, Uwe Grützner, et al.
Cancers|October 22, 2020
Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center AnalysisMonika Karin, Julian Taugner, Lukas Käsmann, et al.
Cancers|April 3, 2021
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World SettingJulian Taugner, Lukas Käsmann, Chukwuka Eze, et al.
Therapeutic Advances in Respiratory Disease|November 24, 2023
Hyperinflation and reduced diffusing capacity predict prognosis in SCLC: value of extended pre-therapeutic lung function testingKathrin Kahnert, Lilli Maria Lempert, Jürgen Behr, et al.
The Annals of Thoracic Surgery|May 15, 2012
Thoracoscopic resection of a giant midesophageal diverticulumChristian L Galata, Christiane J Bruns, Sebastian Pratschke, et al.
BMC Public Health|July 31, 2025
Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients - a claims data analysisJulia Walter, Blerina Resuli, Laura Sellmer, et al.
Pneumologie (Stuttgart, Germany)|December 6, 2024
[Neoadjuvant therapy for resectable non-small cell lung cancer]Katrin Welcker, Danny Jonigk, Cornelia Kropf-Sanchen, et al.
Pageof 15

Showing results (31-40 of 146) with videos related to

Sort By:
Pageof 15
Scientific Reports|May 26, 2021
Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective studyDiego Kauffmann-Guerrero, Kathrin Kahnert, Rosemarie Kiefl, et al.
Therapeutic Advances in Medical Oncology|June 28, 2021
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studiesChristiane Bickert, Kathrin Kahnert, Diego Kauffmann-Guerrero, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal AssessmentDiego Kauffmann-Guerrero, Julian Taugner, Chukwuka Eze, et al.
The Journal of Surgical Research|October 4, 2011
Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injurySebastian Pratschke, Manfred Bilzer, Uwe Grützner, et al.
Cancers|October 22, 2020
Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center AnalysisMonika Karin, Julian Taugner, Lukas Käsmann, et al.
Cancers|April 3, 2021
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World SettingJulian Taugner, Lukas Käsmann, Chukwuka Eze, et al.
Therapeutic Advances in Respiratory Disease|November 24, 2023
Hyperinflation and reduced diffusing capacity predict prognosis in SCLC: value of extended pre-therapeutic lung function testingKathrin Kahnert, Lilli Maria Lempert, Jürgen Behr, et al.
The Annals of Thoracic Surgery|May 15, 2012
Thoracoscopic resection of a giant midesophageal diverticulumChristian L Galata, Christiane J Bruns, Sebastian Pratschke, et al.
BMC Public Health|July 31, 2025
Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients - a claims data analysisJulia Walter, Blerina Resuli, Laura Sellmer, et al.
Pneumologie (Stuttgart, Germany)|December 6, 2024
[Neoadjuvant therapy for resectable non-small cell lung cancer]Katrin Welcker, Danny Jonigk, Cornelia Kropf-Sanchen, et al.
Pageof 15